Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 26Prostatic Neoplasms 15Carcinoma, Non-Small-Cell Lung 10Sarcoma 9Lung Neoplasms 6Uterine Cervical Neoplasms 5Endometrial Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Pancreatic Neoplasms 3Neoplasms 3Liposarcoma, Myxoid 3Head and Neck Neoplasms 3Glioblastoma 3Carcinoma, Intraductal, Noninfiltrating 3Breast Carcinoma In Situ 3Urogenital Neoplasms 2Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma, Synovial 2Radiation Injuries 2Neurofibrosarcoma 2Neoplasm Metastasis 2Melanoma 2Lymphatic Metastasis 2Liposarcoma 2Leiomyosarcoma 2Histiocytoma, Malignant Fibrous 2Fibrosarcoma 2Cholangiocarcinoma 2

Interventions

Gemcitabine 4Cisplatin 4pembrolizumab 3Carboplatin 3erdafitinib 2durvalumab 2vinflunine 1tremelimumab 1niraparib 1enfortumab vedotin 1cabozantinib 1atezolizumab 1Tiragolumab 1Sunitinib 1Radiotherapy 1Radiation Dose Hypofractionation 1Paclitaxel 1Nivolumab 1Midazolam 1Metformin 1Ipilimumab 1Everolimus 1Docetaxel 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Urothelial Cancer × Radiation Dose Hypofractionation × Clear all
NCT02880345 2019-04-23

RADVAXâ„¢: A Trial of Combined Pembrolizumab and Hypofractionated Radiation in Patients With Advanced Urothelial Cancer Who Have Progressed on Anti-PD-1/PD-L1 Monotherapy

Abramson Cancer Center at Penn Medicine

Phase 1 Withdrawn
Genitourinary

Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡